FDA Grants NRx Expanded Access Protocol For NRX-101 In Treating Depression

NRx Pharmaceuticals received an Expanded Access Protocol from the U.S. FDA to facilitate use of NRX-101, its compounded D-cycloserine and lurasidone drug. The authorization supports access to the treatment in a clinical setting and represents a positive regulatory step for the company. The news is favorable but likely limited in immediate market impact absent broader efficacy or commercialization data.

Analysis

NRx Pharmaceuticals received an Expanded Access Protocol from the U.S. FDA to facilitate use of NRX-101, its compounded D-cycloserine and lurasidone drug. The authorization supports access to the treatment in a clinical setting and represents a positive regulatory step for the company. The news is favorable but likely limited in immediate market impact absent broader efficacy or commercialization data.